Naltrexone Extended Release Linked To Lower Rates of Opioid-Use Relapse

Naltrexone Implants
Extended-release naltrexone releases medicine to block the euphoric effects of opioids for 1 month following injection in most patients. A new study examined naltrexone’s effects among adult offenders with a history of opioid dependence.

Extended-release naltrexone releases medicine to block the euphoric effects of opioids for 1 month following injection in most patients. A new study examined naltrexone’s effects among adult offenders with a history of opioid dependence. For the five-site, open-label, randomized trial, 153 participants received a 24-week course of extended-release naltrexone, while 155 individuals received usual treatment (brief counseling and referrals). Individuals in the naltrexone group had a longer median time to relapse (10.5 weeks vs. 5 weeks), a lower rate of relapse (43% vs. 64%), and a higher rate of opioid-negative urine samples (74% vs. 56%). The prevention of opioid use by extended-release naltrexone did not persist at 6 months and 12 months post-treatment. Additionally, the researchers note that ER naltrexone did not affect rates of cocaine, heavy alcohol, and injection-drug use. After 1 year, no overdoses were reported in the naltrexone group, compared with seven in the usual treatment group.

Find out more about naltrexone implants by clicking on the link and viewing the video.

Source Artices: http://www.pharmacist.com/er-naltrexone-linked-lower-rates-opioid-use-relapse

http://www.nejm.org/doi/full/10.1056/NEJMoa1505409

Related posts

Leave a Comment